Taysha Gene Therapies, Inc. TSHA Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenueCurrent.
The official record: Taysha Gene Therapies, Inc.’s 10-Q, filed November 4, 2025, on SEC EDGAR. View the filing →
Ask your AI about Taysha Gene Therapies, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Taysha Gene Therapies, Inc.'s deferred revenue?
- Taysha Gene Therapies, Inc. (TSHA) reported deferred revenue of $5.49M in Q3 2025.
- How has Taysha Gene Therapies, Inc.'s deferred revenue changed year-over-year?
- Taysha Gene Therapies, Inc.'s deferred revenue decreased by 53.5% year-over-year, from $11.8M to $5.49M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s deferred revenue?
- Over 2 years (2022 to 2024), Taysha Gene Therapies, Inc.'s deferred revenue has grown at a -46.0% compound annual growth rate (CAGR), from $33.56M to $9.77M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.